These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 3929265)

  • 1. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
    Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG
    Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of advanced cancer of the prostate with an analog of LHRH, buserelin].
    Wenderoth UK; Jacobi GH
    Ann Urol (Paris); 1986; 20(2):95-7. PubMed ID: 3087269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog].
    Fuse H; Akimoto S; Akakura K; Shimazaki J; Murakami S
    Hinyokika Kiyo; 1988 Mar; 34(3):555-60. PubMed ID: 3133936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment with D-Trp-6-LHRH. Plasma levels and gonadotropic response].
    Lahlou N; Duchier J; Feinstein MC; Mauvernay RY; Roger M; Schally AV
    Pathol Biol (Paris); 1984 Oct; 32(8):906-8. PubMed ID: 6209605
    [No Abstract]   [Full Text] [Related]  

  • 5. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical experience with single and multiple subcutaneous administration of LHRH analog Buserelin (Hoe 766) in prostatic carcinoma: endocrinological study of optimum subcutaneous doses].
    Niijima T; Isurugi K; Kawabe K; Kinoshita K; Asano M; Nakauchi K; Fujita K; Nishimura Y; Nitoh H; Yokoyama M
    Hinyokika Kiyo; 1988 Jul; 34(7):1297-307. PubMed ID: 2459944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.
    Waxman JH; Wass JA; Hendry WF; Whitfield HN; Besser GM; Malpas JS; Oliver RT
    Br Med J (Clin Res Ed); 1983 Apr; 286(6374):1309-12. PubMed ID: 6404441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic prostate cancer under long term pernasal buserelin or intramuscular decapeptyl depot treatment.
    Wenderoth UK; Spindler HW; Ehrenthal W; von Wallenberg H; Happ J; Jacobi GH
    Prog Clin Biol Res; 1987; 243A():207-20. PubMed ID: 2958851
    [No Abstract]   [Full Text] [Related]  

  • 9. Kinetic evaluation of the effect of LHRH analog on prostatic cancer using transrectal ultrasonotomography.
    Kojima M; Watanabe H; Ohe H; Miyashita H; Inaba T
    Prostate; 1987; 10(1):11-7. PubMed ID: 3103113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
    Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Sonoda T
    Hinyokika Kiyo; 1987 Jan; 33(1):141-50. PubMed ID: 2953179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment].
    Oka H; Negoro H; Sugino Y; Iwamura H; Moroi S; Kawakita M
    Hinyokika Kiyo; 2003 Sep; 49(9):521-5. PubMed ID: 14598689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of buserelin on the hormonal states in PCOD.
    Willemsen WN; Franssen AM; Rolland R; Vemer HM
    Prog Clin Biol Res; 1986; 225():377-89. PubMed ID: 3097673
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of prostatic cancer with an LH-RH analog].
    Fuse H; Zama S; Akimoto S; Shimazaki J; Murakami S; Igarashi T
    Hinyokika Kiyo; 1986 Aug; 32(8):1113-9. PubMed ID: 3098063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
    Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
    J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist.
    Allen JM; O'Shea JP; Mashiter K; Williams G; Bloom SR
    Br Med J (Clin Res Ed); 1983 May; 286(6378):1607-9. PubMed ID: 6221774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of LH-RH agonists on the growth and hormonal environment of breast and prostate cancer.
    Nicholson RI; Walker KJ
    Chemioterapia; 1985 Jun; 4(3):249-51. PubMed ID: 3161643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Phase I study with LH-RH agonist, ICI 118630].
    Usami M; Kotake T; Sonoda T
    Hinyokika Kiyo; 1986 Mar; 32(3):493-501. PubMed ID: 2942018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostatic cancer: treatment with long-acting LHRH analogue.
    Williams G; Allen JM; O'Shea JP; Mashiter K; Doble A; Bloom SR
    Br J Urol; 1983 Dec; 55(6):743-6. PubMed ID: 6228283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
    Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
    J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained suppression of testosterone production by the luteinising-hormone releasing-hormone agonist buserelin in patients with advanced prostate carcinoma. A new therapeutic approach?
    Borgmann V; Hardt W; Schmidt-Gollwitzer M; Adenauer H; Nagel R
    Lancet; 1982 May; 1(8281):1097-9. PubMed ID: 6122893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.